STOCK TITAN

Holder plans 15,500-share AMLX sale on NASDAQ (AMLX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

This notice reports a planned sale under Rule 144 of 15,500 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of $227,593. The issuer had 3,363,965 shares outstanding at the time noted.

The securities to be sold were acquired on 02/02/2026 through the vesting of 31,667 restricted stock units. Over the prior three months, the same holder sold additional common shares, including 136,193 shares on 01/15/2026, 7,715 shares on 01/06/2026, and 1,974 shares on 01/16/2026, for disclosed gross proceeds. The signer confirms they are not aware of undisclosed material adverse information about the issuer.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for AMLX disclose?

The Form 144 filing discloses a planned sale of 15,500 common shares through a broker on the NASDAQ. It also lists prior sales over the past three months and confirms the signer knows no undisclosed material adverse information about the issuer.

How many AMLX shares are planned to be sold under this Form 144?

The filing shows a planned sale of 15,500 shares of common stock with an aggregate market value of $227,593. These shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ exchange around 02/02/2026.

How were the AMLX shares in this Form 144 acquired?

The shares were acquired through the vesting of 31,667 restricted stock units on 02/02/2026. The filing identifies the issuer as the source of these shares and notes that the vesting event served as the acquisition and payment date.

What prior AMLX share sales are listed in the last three months?

The notice lists three prior common stock sales: 7,715 shares sold on 01/06/2026, 136,193 shares sold on 01/15/2026, and 1,974 shares sold on 01/16/2026, each with corresponding gross proceeds disclosed in dollars.

How many AMLX shares were outstanding when this Form 144 was prepared?

The filing reports 3,363,965 shares of common stock outstanding. This figure provides context for the relative size of the planned Rule 144 sale compared with the issuer’s total share count at the referenced time.

What representation does the seller make in this AMLX Form 144?

The signer represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, consistent with Rule 144 requirements for sales by affiliates or other covered persons.
Amylyx Pharmaceuticals

NASDAQ:AMLX

AMLX Rankings

AMLX Latest News

AMLX Latest SEC Filings

AMLX Stock Data

1.43B
91.52M
9.5%
94.68%
9.43%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE